Skip to main content
Premium Trial:

Request an Annual Quote

Tammy Mullarky, Peter Lutwyche, John Schmidt, Victor Kotelianski, Antonin de Fougerolles, Susanna High, Dinah Sah, Bryan Dunnivant

Premium
Tekmira Pharmaceuticals has named Tammy Mullarky as its vice president of strategic planning and business development, and Peter Lutwyche as vice president of pharmaceutical development.
 
Mullarky previously served as senior vice president of crop biotechnology firm Targeted Growth. Before that, she was a senior executive at Epigenomics, a cancer molecular diagnostics company.
 
She holds an MA in science management from the Massachusetts Institute of Technology and a BA in chemistry from Whitman College.
 
Lutwyche was formerly with Protiva Biotherapeutics, which merged with Tekmira earlier this year (see RNAi News, 4/3/2008). Before that, he held a number of positions, most recently director of pharmaceutical development, at QLT.
 
He holds a PhD in chemistry from the University of British Columbia.
 

 
Alnylam Pharmaceuticals has named John Schmidt as its CSO.
 
Schmidt was previously vice president and US member of the Sanofi-Aventis Global Discovery Leadership Team. Prior to Aventis’ merger with Sanofi-Synthelabo, Schmidt was Aventis’ vice president and head of the respiratory and rheumatoid arthritis disease group. He also served as senior director of immunology and rheumatology at Merck Research Laboratories.
 
Schmidt holds an MD from the University of Pennsylvania.
 
Alnylam also said it has promoted Victor Kotelianski to the newly created position of senior vice president and distinguished Alnylam fellow. He was previously vice president of research.
 
Additionally, the company has promoted Antonin de Fougerolles to the position of vice president of research, immunology, metabolic, and viral disease; Susanna High to the position of vice president of business planning and program management; and Dinah Sah to the position of vice president of research, CNS, and oncology.
 

 
Intradigm has appointed Bryan Dunnivant, a principal at investment group Lilly Ventures, to its board of directors.
 
Dunnivant is joining the board in connection with Lilly Ventures’ participation in Intradigm’s Series B financing round (see related story, this issue).

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.